Rosa I. Gallagher

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Denise M. Wolf, Christina Yau, Julia Wulfkuhle et al. · Cancer Cell · 2022 · 326 citations · Full text

Medicine, Cancer Biology, Oncology +17

Malignant Precursor Cells Pre-Exist in Human Breast DCIS and Require Autophagy for Survival

Virginia Espina, Brian D. Mariani, Rosa I. Gallagher et al. · PLoS ONE · 2010 · 149 citations · Full text

Medicine, Cell Biology, Oncology +17

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models

Wenle Xia, Emanual Petricoin, Sumin Zhao et al. · Breast Cancer Research · 2013 · 143 citations · Full text

Medicine, Oncology, Pharmacology +17

Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon et al. · Blood Advances · 2017 · 115 citations · Full text

Life Sciences, Immunology, Pharmacology +11

Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer

Mariaelena Pierobon, Corinne Ramos, Shukmei Wong et al. · Clinical Cancer Research · 2017 · 96 citations

Medicine, Cancer Biology, Oncology +17